COMPANY

VeraMorph LLC

VeraMorph has a proprietary oral drug delivery platform for poorly soluble compounds, used with partner companies and to build oral versions of approved drugs. From company website Source · Oct 12, 2026

Keywords: drug delivery specialty pharma

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $935K (SBIR Phase II 4R44CA306533-02, extension, notice Sep 11, 2026). NIH RePORTER 4R44CA306533-02 (Sep 11, 2026)
Evidence (1 event)
- Sep 11, 2026 · NIH RePORTER 4R44CA306533-02
  Organization: VERAMORPH, LLC; City/State: NORWOOD, MA; Project number: 4R44CA306533-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 935236; Administering IC: National Cancer Institute; Project title: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals